Your browser doesn't support javascript.
loading
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy.
Martini, Alberto; Wever, Lieke; Soeterik, Timo F W; Rakauskas, Arnas; Fankhauser, Christian Daniel; Grogg, Josias Bastian; Checcucci, Enrico; Amparore, Daniele; Haiquel, Luciano; Rodriguez-Sanchez, Lara; Ploussard, Guillaume; Qiang, Peng; Affentranger, Andres; Marquis, Alessandro; Marra, Giancarlo; Ettala, Otto; Zattoni, Fabio; Falagario, Ugo Giovanni; De Angelis, Mario; Kesch, Claudia; Apfelbeck, Maria; Al-Hammouri, Tarek; Kretschmer, Alexander; Kasivisvanathan, Veeru; Preisser, Felix; Lefebvre, Emilie; Olivier, Jonathan; Radtke, Jan Philipp; Carrieri, Giuseppe; Moro, Fabrizio Dal; Boström, Peter; Jambor, Ivan; Gontero, Paolo; Chiu, Peter K; John, Hubert; Macek, Petr; Porpiglia, Francesco; Hermanns, Thomas; van den Bergh, Roderick C N; van Basten, Jean-Paul A; Gandaglia, Giorgio; Valerio, Massimo.
Afiliación
  • Martini A; Department of Urology, La Croix du Sud Hospital, Toulouse, France. a.martini.md@gmail.com.
  • Wever L; St. Antonius ziekenhuis, Nieuwegein, the Netherlands.
  • Soeterik TFW; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.
  • Rakauskas A; St. Antonius ziekenhuis, Nieuwegein, the Netherlands.
  • Fankhauser CD; Department of Urology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Grogg JB; Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Checcucci E; Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Amparore D; Department of Urology, San Luigi Hospital, Turin, Italy.
  • Haiquel L; Department of Urology, San Luigi Hospital, Turin, Italy.
  • Rodriguez-Sanchez L; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Ploussard G; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Qiang P; Department of Urology, La Croix du Sud Hospital, Toulouse, France.
  • Affentranger A; SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
  • Marquis A; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
  • Marra G; Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
  • Ettala O; Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
  • Zattoni F; Department of Urology, Turku University, Turku, Finland.
  • Falagario UG; Urology Unit, Academical Medical Centre Hospital, Udine, Italy.
  • De Angelis M; Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, Padua, Italy.
  • Kesch C; Department of Urology, University of Foggia, Foggia, Italy.
  • Apfelbeck M; Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.
  • Al-Hammouri T; Department of Urology, University Hospital Essen, Essen, Germany.
  • Kretschmer A; German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Kasivisvanathan V; Department of Urology, LMU, Munich, Germany.
  • Preisser F; Department of Urology, University College London and University College London Hospitals NHS Foundation Trust, London, UK.
  • Lefebvre E; Department of Urology, LMU, Munich, Germany.
  • Olivier J; Department of Urology, University College London and University College London Hospitals NHS Foundation Trust, London, UK.
  • Radtke JP; Department of Urology, University Hospital Frankfurt, Frankfurt, Germany.
  • Carrieri G; Department of Urology, CHU Lille, Lille, France.
  • Moro FD; Department of Urology, CHU Lille, Lille, France.
  • Boström P; Department of Urology, University Hospital Essen, Essen, Germany.
  • Jambor I; German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
  • Gontero P; Department of Urology, University of Foggia, Foggia, Italy.
  • Chiu PK; Urology Unit, Academical Medical Centre Hospital, Udine, Italy.
  • John H; Department of Surgery, Oncology, and Gastroenterology, Urology Clinic, University of Padua, Padua, Italy.
  • Macek P; Department of Urology, Turku University, Turku, Finland.
  • Porpiglia F; Department of Urology, Turku University, Turku, Finland.
  • Hermanns T; Department of Urology, San Giovanni Battista Hospital, University of Turin, Turin, Italy.
  • van den Bergh RCN; SH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
  • van Basten JA; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
  • Gandaglia G; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Valerio M; Department of Urology, San Luigi Hospital, Turin, Italy.
Article en En | MEDLINE | ID: mdl-38182804
ABSTRACT

PURPOSE:

Accurate prediction of extraprostatic extension (EPE) is pivotal for surgical planning. Herein, we aimed to provide an updated model for predicting EPE among patients diagnosed with MRI-targeted biopsy. MATERIALS AND

METHODS:

We analyzed a multi-institutional dataset of men with clinically localized prostate cancer diagnosed by MRI-targeted biopsy and subsequently underwent prostatectomy. To develop a side-specific predictive model, we considered the prostatic lobes separately. A multivariable logistic regression analysis was fitted to predict side-specific EPE. The decision curve analysis was used to evaluate the net clinical benefit. Finally, a regression tree was employed to identify three risk categories to assist urologists in selecting candidates for nerve-sparing, incremental nerve sparing and non-nerve-sparing surgery.

RESULTS:

Overall, data from 3169 hemi-prostates were considered, after the exclusion of prostatic lobes with no biopsy-documented tumor. EPE was present on final pathology in 1,094 (34%) cases. Among these, MRI was able to predict EPE correctly in 568 (52%) cases. A model including PSA, maximum diameter of the index lesion, presence of EPE on MRI, highest ISUP grade in the ipsilateral hemi-prostate, and percentage of positive cores in the ipsilateral hemi-prostate achieved an AUC of 81% after internal validation. Overall, 566, 577, and 2,026 observations fell in the low-, intermediate- and high-risk groups for EPE, as identified by the regression tree. The EPE rate across the groups was 5.1%, 14.9%, and 48% for the low-, intermediate- and high-risk group, respectively.

CONCLUSION:

In this study we present an update of the first side-specific MRI-based nomogram for the prediction of extraprostatic extension together with updated risk categories to help clinicians in deciding on the best approach to nerve-preservation.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Francia
...